🧪 Metformin Cancer Risk Reduction Epidemiology Simulator

Lower Cancer Incidence Observed in Metformin Users

Retrospective cohorts repeatedly reported reduced cancer rates in metformin-treated patients.

• 40+: Studies reviewed (Placeholder summary figure)
• 10–40%: Reported RRR range (Placeholder summary figure)
• Multiple: Cancer types flagged (Placeholder summary figure)
• Retrospective: Study design (Placeholder summary figure)

Early observational findings

Placeholder: initial registry studies noted a consistent association.

Comparing Diabetic Treatment Cohorts

Metformin users are compared to sulfonylurea or insulin users within diabetic registries.

• ~100k: Cohort size (Placeholder summary figure)
• 5–10 yrs: Follow-up (Placeholder summary figure)
• 2–3: Comparator arms (Placeholder summary figure)
• ~15: Adjustment variables (Placeholder summary figure)

Cohort construction approach

Placeholder: matched cohorts built from insurance and registry databases.

Anti-Proliferative Mechanisms Proposed

AMPK activation and mTOR pathway suppression are candidate mechanisms.

• AMPK/mTOR: Key pathway (Placeholder summary figure)
• Reduced growth: In vitro effect (Placeholder summary figure)
• Lowered: Insulin axis (Placeholder summary figure)
• Preclinical: Evidence tier (Placeholder summary figure)

Candidate biological pathways

Placeholder: laboratory studies suggest plausible tumor-suppressive pathways.

Confounding by Indication Undermines Causal Claims

Prescribing patterns may systematically favor healthier patients for metformin.

• Indication bias: Bias type (Placeholder summary figure)
• Likely present: Healthy-user effect (Placeholder summary figure)
• Possible: Immortal time bias (Placeholder summary figure)
• Residual confounding: Adjustment limits (Placeholder summary figure)

Sources of systematic bias

Placeholder: sicker patients often avoid metformin due to renal contraindications.

Placeholder: confounding by indication can fully explain observed associations.

Randomized Trials Required for Causal Proof

Prospective randomized trials are the only way to confirm a true drug effect.

• Few: Ongoing RCTs (Placeholder summary figure)
• Thousands: Trial size needed (Placeholder summary figure)
• Inconclusive: Current status (Placeholder summary figure)
• High: Priority (Placeholder summary figure)

Path to definitive evidence

Placeholder: large randomized trials remain the necessary next step.